Companies: 10,795·Total market cap: $144.5T

Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics Inc.

IMDXNASDAQHealthcare● Active

$5.72

+$0.48(+9.16%)

Market Cap$153533168

P/E Ratio—

52W High$8.51

52W Low$2.33

Avg Volume350K

Open$5.30

Beta1.79

Net Income Financials Revenue

Insight Molecular Diagnostics Inc. (IMDX) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

IMDX · net income · updated Jun 9, 2026

Core profitability metrics

IMDX · net income · margin · TTM · CAGR

Net income was −$50.2M for FY2025 (fiscal year ending 2025-12-31), up 17.2% year-over-year. Net profit margin was -1238.5%.

FY2025 Net Income−$50.2M▲ +17.2% YoY

Trailing 12M (TTM)−$47.8Mtrailing 4 quarters sum

Net Profit Margin< −999%−$50.2M ÷ $4.1M

YoY Change+17.2%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · IMDX net income history · IMDX profit margin

Annual net income data

IMDX · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$50.2M▲ +17.2%-1238.5%$4.1M

FY2024Loss−$60.7M▼ 118.4%-3225.0%$1.9M

FY2023Loss−$27.8M▲ +61.9%-1848.4%$1.5M

FY2022Loss−$72.9M▼ 13.7%-7609.8%$958,000

FY2021Loss−$64.1M▼ 114.1%-2916.2%$2.2M

Net income vs peers (Healthcare)

IMDX vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

#1

Insight Molecular Diagnostics Inc.YOU

IMDX

−$50.2M+17.2%-1238.5%

Loss

Johnson & Johnson

$26.80B+90.6%28.5%

Eli Lilly and Company

$20.64B+94.9%31.7%

UnitedHealth Group Incorporated

$12.06B-16.3%2.7%

$4.23B-1.2%6.9%

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Insight Molecular Diagnostics Inc. (IMDX) reported net income of −$50.2M for FY2025 (fiscal year ending 2025-12-31), up 17.2% year-over-year. The net profit margin was -1238.5% — meaning the company kept $-12.39 of every dollar of revenue as profit.

Insight Molecular Diagnostics Inc. has not yet achieved annual profitability based on available data (13 fiscal years). The company has reported net losses across all available periods.

Insight Molecular Diagnostics Inc.'s net profit margin was -1238.5% for FY2025, based on the latest annual results.

Investors sometimes search for "Insight Molecular Diagnostics Inc. net worth" — the company's market capitalization is a separate figure from IMDX net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

IMDX net income · 4 questions

Insight Molecular Diagnostics Inc. is not currently profitable on an annual basis. The company reported a net loss of $50.2M for FY2025.

is IMDX profitabledoes IMDX make a profitIMDX profitabilityIMDX profitable company

▸ Source: FMP /income-statement · GAAP · Insight Molecular Diagnostics Inc. · Insight Molecular Diagnostics Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026